Tag: THERADIAG
Theradiag: 2022 turnover without surprise
(CercleFinance.com) – The Theradiag share rose slightly by 0.7% on the Paris Stock Exchange on Monday, investors being reassured by the unsurprising activity figures published in the morning by the…
Theradiag: 2022 revenue up 9.7% – 01/16/2023 at 8:49 am
(AOF) – Theradiag reported annual revenue for 2022 of 12.2 million euros, up 9.7%. The company specializing in in vitro diagnostics generated 55% of its turnover abroad, compared to 52%…
THERADIAG: 2022 annual revenue of €12.2 million, up 9.7% – 01/16/2023 at 07:30
• Solid growth of +10.1% in Theranostics and +9.2% in IVD • Good export performance (outside the United States) materialized by an increase of +23.3% • Cash level as of…
Theradiag press release in response to the takeover bid for Theradiag shares initiated by Biosynex – 2022-11-02 at 6:00 p.m.
Theradiag press release in response to the public takeover bid for Theradiag shares initiated by Biosynex This press release has been prepared and is distributed pursuant to the provisions of…
Theradiag appoints an independent expert to examine Biosynex’s offer
By Alexandra Saintpierre Published on 03/10/2022 at 06:53 Photo credit © Reuters (Boursier.com)…
Biosynex: Theradiag appoints an independent expert within the framework of the takeover bid – 09/30/2022 at 18:19
(AOF) – Theradiag has announced the appointment of the firm Crowe HAF by the company’s board of directors as an independent expert within the framework of the proposed voluntary takeover…
Theradiag: Appointment of an independent expert – 2022-09-30 at 17:35
Croissy-Beaubourg, September 30, 2022, 5:35 p.m. CEST – THERADIAG (ISIN: FR0004197747, Mnemonic: ALTER), a company specializing in in vitro diagnostics and theranostics, announces the appointment of Crowe HAF by the…
Biosynex takes on Theradiag
No truce for Biosynex. The medtech, which has been successful thanks to its self-tests, has embarked on a vast external growth plan, which results in a takeover offer for Theradiag.…
Theradiag targeted for a takeover bid by Biosynex – 09/23/2022 at 17:28
(AOF) – Biosynex has filed a takeover bid with the AMF for Theriagag at a price of 2.30 euros per share, representing a premium of 58.62% respectively on the closing…
Theradiag: Biosynex files a takeover bid with the AMF
(CercleFinance.com) – Theradiag announces that Biosynex has filed a voluntary takeover bid in cash with the Autorité des marchés financiers for the shares of the Company that it does not…
BREF – Biosynex announces a proposed takeover bid for Theradiag at a price of €2.30 per share
BREF – Biosynex announces a proposed takeover bid for Theradiag at a price of €2.30 per share | Photo credits: Biosynex Sept 23 (Reuters) – Biosynex says it has filed…
Biosynex: files a takeover bid on Theradiag shares
(CercleFinance.com) – Theradiag announces that Biosynex has filed a voluntary takeover bid in cash with the Autorité des marchés financiers for the shares of the Company that it does not…